Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 8/20 | 0.58 |
| ▸ | CYP19A1 | P11511 | 8/20 | 0.37 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.35 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.33 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.33 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.33 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5358210 | 0.91 | AR (0.47) | ARCYP19A1PIN1BAZ2BBAZ2A | |
| SCHEMBL5362174 | 0.88 | AR (0.44) | ARCYP19A1PIN1 | |
| SCHEMBL5369671 | 0.84 | AR (0.60) | ARGRIA2GRIA4 | |
| SCHEMBL6466386 | 0.82 | AR (0.58) | ARCYP19A1BAZ2BBAZ2AGRIA2 | |
| SCHEMBL5365095 | 0.82 | AR (0.65) | ARCYP19A1GRIA2GRIA4 | |
| SCHEMBL5358573 | 0.79 | AR (0.54) | ARGRIA2GRIA4 | |
| SCHEMBL6466161 | 0.76 | AR (0.58) | ARGRIA2GRIA4 | |
| SCHEMBL6469428 | 0.71 | AR (0.58) | ARCYP19A1GRIA2GRIA4 | |
| SCHEMBL6466987 | 0.71 | AR (0.58) | ARGRIA2GRIA4 | |
| SCHEMBL5362232 | 0.71 | AR (0.61) | ARCYP19A1GRIA2GRIA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050101657-A1 | Pyrrole derivatives for preventing or treating cancer sensitive to hormones; administered with luteininzing hormone releasing hormone derivative | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1466902-A1 | ANDROGEN RECEPTOR ANTAGONISTS | Takeda Chemical Industries, Ltd. (JP) | 2004-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101657-A1 | Pyrrole derivatives for preventing or treating cancer sensitive to hormones; administered with luteininzing hormone releasing hormone derivative | SHBG, PRLHR, FSHR | AR 6/4885CYP19A1 38/4885PIN1 1023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.